home

Breaking News

Redox Signs Licensing Agreement With OPKO Health, Inc.
On June 12, 2008, OPKO and Redox entered into an agreement whereby OPKO acquired the rights for all ophthalmic uses of Doxovir.

see OPKO Press Release

Redox Pharmaceutical Corporation has been granted approval from Health Canada to perform clinical studies on Herpes Labialis (cold sores).  Phase IB Clinical Trials (initial proof of safety and efficacy) have been successfully completed. A Phase II Clinical Trial on Herpes Labialis has been approved and has now been initiated.


©2008 Redox Pharmaceutical Corporation.
All right reserved.

Send us your site suggestions & service requests.

Site hosted by: Transbeam.com
Prophylactic
Sexually Transmitted Diseases (STDs)
Chlamydia
Chlamydia is the most common sexually transmitted bacterial disease in the United States. It is estimated that more than three million Americans (women and men) become infected with Chlamydia every year. In the U.S., Chlamydia results in 250,000 to 500,000 cases of Pelvic Inflammatory Disease (PID) annually. PID is a serious cause of female infertility. Unfortunately, young women of childbearing age are the single largest group affected by the disease. In most cases, individuals have no symptoms and are unaware of their bacterial infection. Redox Pharmaceutical Corporation has demonstrated in preliminary tests efficacy against Chlamydia infection in animals pre-treated with Doxovir-M™.
Contact Us | Home

MEDICAL APPLICATIONS

Ocular Applications Adenovirus-derived Keratoconjunctivitis Herpetic Keratitis

Genital Applications Overview
HIV
Human Papillomavirus
Genital Herpes
Chlamydia

Dermal Application
Facial Herpes

Anti-Inflammatory Application
Non-Steroidal anti-inflammatory